QT Prolongation Risk with Duloxetine and Gabapentin
Neither duloxetine nor gabapentin cause clinically significant QT interval prolongation at therapeutic doses, and both can be considered safe from a cardiac repolarization standpoint.
Duloxetine
Duloxetine does not prolong the QT interval and may actually cause concentration-dependent QT shortening. 1
The FDA label explicitly states that duloxetine at supratherapeutic doses (160-200 mg twice daily, which is 2.7-3.3 times the maximum recommended dose) showed no QT interval prolongation in a thorough QT study of 117 healthy female subjects 1
A dedicated cardiac electrophysiology study demonstrated that duloxetine at doses up to 200 mg twice daily showed mean QTc decreases compared to placebo, with upper confidence interval limits consistently <0 msec at all time points 2
No subject achieved absolute QTc values >445 msec with duloxetine, and no relationship was detected between QTc changes and plasma concentrations even at exposures 5 times higher than therapeutic levels 2
Importantly, the European Heart Journal guideline on psychotropic medications found that SNRIs (including duloxetine) showed no association with cardiac arrest, in contrast to SSRIs and tricyclic antidepressants which had odds ratios of 1.21 and 1.69 respectively 3
A 2014 systematic review confirmed that existing studies fail to demonstrate QT prolongation with duloxetine, with the highest risk for non-SSRI antidepressants being limited to venlafaxine and bupropion in overdose situations 4
Gabapentin
Gabapentin (and its prodrug gabapentin enacarbil) does not cause QT prolongation even at supratherapeutic doses. 5
A definitive thorough QT/QTc study conducted per ICH E14 guidance evaluated gabapentin enacarbil at both therapeutic (1200 mg) and supratherapeutic (6000 mg) doses in 54 healthy adults 5
The maximum change in QTc was only 0.7 msec (upper 95% CI: 3.0) at 1200 mg and 1.3 msec (upper 95% CI: 3.6) at 6000 mg—both well below the 10 msec threshold of clinical concern 5
The European Heart Journal guideline specifically addresses anticonvulsants used as mood stabilizers, stating that anticonvulsants have generally not been associated with severe arrhythmia 3
Gabapentin exposures were dose-proportional, and no QT-concentration relationship was detected at any dose level 5
Clinical Implications
Both medications can be prescribed without routine ECG monitoring for QT prolongation concerns in patients without other significant cardiac risk factors. 3, 1, 5
Key Caveats:
While these drugs themselves don't prolong QT, patients with pre-existing cardiac conditions (heart failure, ischemic heart disease, inherited long QT syndrome) remain at baseline elevated risk for arrhythmias regardless of medication choice 3
Duloxetine should still be avoided in patients with substantial alcohol use due to hepatotoxicity risk, not cardiac concerns 1
Duloxetine can cause modest blood pressure increases (mean 0.5 mmHg systolic, 0.8 mmHg diastolic), which requires monitoring but is unrelated to QT effects 1
Drug interactions remain important: duloxetine is metabolized by CYP1A2 and CYP2D6, and should not be combined with thioridazine (which does prolong QT) 1